Lilly Requests Revocation of Emergency Use Authorization for Bamlanivimab Alone to Complete Transition to Bamlanivimab and Etesevimab Together for Treatment of COVID-19 in the U.S.

INDIANAPOLIS, April 16, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) has requested the U.S. Food and Drug Administration (FDA) revoke the Emergency Use Authorization (EUA) for bamlanivimab (LY-CoV555) 700 mg alone. Lilly made...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials